Advances in cell and gene therapies (CGT) are credited with thoroughly transforming medicinal science and creating an inflection point in the ability…

Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety.  Levy…

The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals…

Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer…

Certara's Ulrich Neumann examines some of the major US market access trends of the past few years, including the innovative financing models required…

Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in…

Rare disease patient advocate Monica Weldon outlines some of the ethical conundrums around embryonic gene editing. With CRISPR technology again in the…

Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for…

On 7 October 2020, the 2020 Nobel Prize in Chemistry was jointly awarded to Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a…

Professor Nicolaus Kröger, president of the European Society for Blood and Marrow Transplantation (EBMT) introduces the multi-stakeholder GoCART…

Genomic medicine expert Professor Thomas D. Szucs explains what ignited his interest in the field and how payers and authorities are adapting to the…

The EMA’s Head of Advanced Therapies Dr Ana Hidalgo-Simon outlines Europe’s evolving regulatory framework for regenerative medicines, how it…